Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales.

ABSTRACT:

Introduction

Carbapenems (CR) have traditionally been the first line treatment for bacteremia caused by AmpC-producing Enterobacterales. However, CR have a high ecological impact, and carbapenem-resistant strains continue rising. Thus, other treatment alternatives like Piperacillin-Tazobactam (P-T) or Cefepime (CEF) and oral sequential therapy (OST) are being evaluated.

Methods

We conducted a retrospective, single-centre observational study. All adult patients with AmpC-producing Enterobacterales bacteremia were included. The primary endpoint was clinical success defined as a composite of clinical cure, 14-day survival, and no adverse events. We evaluated the evolution of patients in whom OST was performed.

Results

Seventy-seven patients were included, 22 patients in

SUBMITTER: Avila-Nunez M 

PROVIDER: S-EPMC10436381 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature